No abstract available
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Review
MeSH terms
-
Abciximab
-
Administration, Oral
-
Adult
-
Aged
-
Angina, Unstable / drug therapy
-
Angina, Unstable / therapy
-
Angioplasty, Balloon, Coronary
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use
-
Aspirin / pharmacology
-
Cardiology / methods*
-
Clinical Trials as Topic
-
Coronary Disease / blood
-
Coronary Disease / drug therapy
-
Coronary Disease / prevention & control
-
Coronary Disease / therapy
-
Double-Blind Method
-
Embolism / prevention & control
-
Eptifibatide
-
Female
-
Fibrinolytic Agents / adverse effects
-
Fibrinolytic Agents / therapeutic use
-
Follow-Up Studies
-
Forecasting
-
Hemorrhage / chemically induced
-
Humans
-
Immunoglobulin Fab Fragments / adverse effects
-
Immunoglobulin Fab Fragments / therapeutic use
-
Male
-
Meta-Analysis as Topic
-
Middle Aged
-
Multicenter Studies as Topic
-
Myocardial Infarction / drug therapy
-
Myocardial Infarction / therapy
-
Peptides / adverse effects
-
Peptides / therapeutic use
-
Platelet Aggregation / drug effects*
-
Platelet Aggregation Inhibitors / administration & dosage
-
Platelet Aggregation Inhibitors / adverse effects
-
Platelet Aggregation Inhibitors / pharmacology
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
-
Platelet Glycoprotein GPIIb-IIIa Complex / chemistry
-
Platelet Glycoprotein GPIIb-IIIa Complex / immunology
-
Prospective Studies
-
Risk
-
Stents
-
Structure-Activity Relationship
-
Tirofiban
-
Treatment Outcome
-
Tyrosine / adverse effects
-
Tyrosine / analogs & derivatives
-
Tyrosine / therapeutic use
Substances
-
Antibodies, Monoclonal
-
Fibrinolytic Agents
-
Immunoglobulin Fab Fragments
-
Peptides
-
Platelet Aggregation Inhibitors
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
Tyrosine
-
Tirofiban
-
Eptifibatide
-
Aspirin
-
Abciximab